Arcus Biosciences Inc (RCUS)

Feb 18, 2025, 6:57 AM EST - 4 days ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 4 days ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 7 days ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 11, 2025, 4:35 PM EST - 11 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Feb 10, 2025, 5:00 PM EST - 12 days ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 4 weeks ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 5 weeks ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 5 weeks ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 2 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 3 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Nov 6, 2024, 11:39 PM EST - 3 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 3 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 3 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 4 months ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 4 months ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 4 months ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 4 months ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 5 months ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 5 months ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 6 months ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 7 months ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 7 months ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 7 months ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 7 months ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 8 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 9 months ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 9 months ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 9 months ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 9 months ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

May 8, 2024, 9:55 PM EDT - 10 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 10 months ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 2, 2024, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Apr 24, 2024, 4:00 PM EDT - 10 months ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 23, 2024, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Feb 22, 2024, 2:08 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Feb 7, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Jan 29, 2024, 6:20 PM EST - 1 year ago

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

GILD

Jan 29, 2024, 5:00 PM EST - 1 year ago

Gilead and Arcus Announce Amended Collaboration and Equity Investment

GILD

Jan 16, 2024, 5:00 PM EST - 1 year ago

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK ITOS MRK NVS

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Dec 15, 2023, 2:25 AM EST - 1 year ago

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 4, 2023, 8:00 AM EST - 1 year ago

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

EXEL

Nov 20, 2023, 2:19 PM EST - 1 year ago

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 14, 2023, 4:00 PM EST - 1 year ago

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 8, 2023, 12:54 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

Nov 6, 2023, 5:00 PM EST - 1 year ago

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

GILD

Nov 6, 2023, 5:00 PM EST - 1 year ago

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

GILD